INmune Bio, Inc. Announces Presentation of Data Related to its Lead Compound XPro1595 at the Society for Neuroscience’s Ann...
October 17 2019 - 09:00AM
INmune Bio, Inc. (NASDAQ: INMB), an immunotherapy company
developing treatments that harness the patient’s innate immune
system to fight disease, announced today a poster presentation
related to the company’s program in Alzheimer’s disease at the
upcoming Society for Neuroscience (SfN) 49th Annual Meeting, to be
held Oct. 19–23 at McCormick Place in Chicago. In addition, INmune
Bio announced that this presentation has been selected for
presentation during the meeting’s press conference.
Presented in a poster by Malú Tansey, Ph.D., Professor of
Neuroscience and Director of the Center for Translational Research
in Neurodegenerative Disease at the University of Florida College
of Medicine, the data from studies involving the use of INmune
Bio’s XPro1595 demonstrate the critical role of the immune system
on an individual's genetic risk in the context of environmental
exposures, such as a diet high in fat and sugar, for
neurodegenerative diseases such as Alzheimer’s. The
Company believes that XPro1595 is a next generation
anti-inflammatory that crosses the blood-brain barrier to affect
neurodegenerative diseases by selectively inhibiting soluble tumor
necrosis factor.
“It’s become clear that neurological disorders can arise from or
be exacerbated by innate immune dysfunction and chronic
inflammation resulting from both genetic and environmental factors
such as diet,” said Dr. Tansey. “Harnessing the power of the immune
system could potentially delay or perhaps even prevent some of
these neurological disorders. Our results provide a compelling
rationale for moving forward with a clinical trial in early
Alzheimer’s disease patients.”
The SfN Annual Meeting is the premier venue for neuroscientists
to present emerging science, learn from experts, forge
collaborations with peers and explore new tools and technologies
related to the brain and the nervous system.
Poster Details
Session: Alzheimer's Disease and Other
Dementias: Therapeutic Strategies III
Poster number: 564
Presentation Title: Soluble tnf mediates
obesogenic diet‑induced alterations in peripheral and brain
immunophenotype in a model of Alzheimer's disease
Time and Date: 1:00 PM, Oct. 22
Location: McCormick Place, Chicago,
Illinois
The presentation abstract can be accessed on the SfN website.
The above listed date may be subject to change. Details on
presentation times or changes to presentation dates can be found on
the SfN website. Please check https://www.sfn.org/ for the latest
information.
About the Society for Neuroscience
(SfN)
The Society for Neuroscience is the world’s largest organization
of scientists and physicians devoted to understanding the brain and
the nervous system. SfN’s mission is to advance the understanding
of the brain and the nervous system by bringing together scientists
of diverse backgrounds, by facilitating the integration of research
and by encouraging translational research and the application of
new scientific knowledge to develop improved disease treatments and
cures. SfN is also committed to provide professional development
activities, information, and educational resources for
neuroscientists at all stages of their careers, to promote public
information and general education about the latest neuroscience
research and inform legislators and other policymakers.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB)
clinical-stage biotechnology company developing therapies targeting
the innate immune system to fight disease. INmune Bio is developing
three product platforms: two products that reengineer the patient’s
innate immune system’s response to cancer and one product to treat
neuroinflammation that is currently focused on Alzheimer’s disease.
INKmune is a natural killer (NK) cell therapeutic that primes the
patient’s NK cells to attack minimal residual disease, the
remaining cancer cells that are difficult to detect, which often
cause a relapse. INB03 inhibits myeloid-derived suppressor cells
(MDSC), which often cause resistance to immunotherapy, such as
anti-PD-1 checkpoint inhibitors. XPro1595 targets
neuroinflammation, which causes microglial activation and neuronal
cell death. INmune Bio’s product platforms utilize a precision
medicine approach for the treatment of a wide variety of
hematologic malignancies, solid tumors and chronic inflammation. To
learn more, please visit www.inmunebio.com.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. Actual results and the timing of certain events
and circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. INBO3 and XPro1595 are still in clinical trials and
have not been approved and there cannot be any assurance that they
will be approved or that any specific results will be achieved. The
factors that could cause actual future results to differ materially
from current expectations include, but are not limited to, risks
and uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K for the year ended December
31, 2018, the Company’s Quarterly Reports on Form 10-Q and the
Company’s Current Reports on Form 8-K. The Company assumes no
obligation to update any forward-looking statements in order to
reflect any event or circumstance that may arise after the date of
this release.
INmune Bio Contact: David Moss, CFO(858)
964-3720DMoss@INmuneBio.com
Media Contact: David SchullRusso Partners(212)
845-4271David.Schull@russopartnersllc.com
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Feb 2024 to Mar 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2023 to Mar 2024